anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention is directed to mammalian cells conjugated to a hapten and methods of making and using thereof. Conjugating hapten to mammalian cells is a useful way of preventing cells from growing and may be used in the place of any conventional treatment, for example, irradiation. Thus, the invention relates to mammalian cells in general, for example human cells, which cells are in substantially no growth phase and a method of placing the cells in a substantially no growth phase by conjugating them to a hapten. The invention is further directed to compositions containing hapten-modified tumor cells and extracts and methods of treating cancer by administering a therapeutically effective amount of a composition containing a tumor cell or tumor cell extract to a subject in need of such treatment. The tumor cells and extracts of the invention and compositions thereof are capable of eliciting T-lymphocytes that have a property of infiltrating a mammalian tumor, eliciting an inflammatory immune response to a mammalian tumor, eliciting a delayed-type hypersensitivity response to a mammalian tumor and/or stimulating T-lymphocytes  in vitro . The invention also relates to an effective vaccination schedule useful for inducing an anti-tumor response in a mammalian patient suffering from cancer by inducing at least one of the following: tumor necrosis, tumor regression, tumor inflammation, tumor infiltration by activated T-lymphocytes, delayed-type hypersensitivity response, and prolongation of patient survival. Furthermore, the invention relates to an improved, simplified and economical method for preparing the hapten-conjugated tumor cells for administration as a vaccine by eliminating a separate step of treating cells (by irradiation, for example) to place them in a no growth phase.
Airway inflammation is an important component of asthma. It influences other components which include symptoms and airway functional (physiological) measurements. It is the primary target of treatment. However, it does not correlate closely with symptoms, need for symptomatic bronchodilator relief, or the physiological abnormalities. Furthermore, it can be of different types. As a result, physicians are poor at recognizing its presence or type. This is important because eosinophilic inflammation is responsive to corticosteroid while non-eosinophilic is not responsive.

The most comprehensive non-invasive or relatively non-invasive measurement of airway inflammation is by spontaneous or induced sputum cell counts. These are reliable, valid and responsive, the qualities of good measurements. They might therefore be clinically useful to guide individual treatment. In the present study we investigated this issue. We compared their use, in comparison with the use only of symptoms and spirometry, in preventing exacerbations of asthma. We chose prevention of exacerbations as the most important clinical outcome because these have the greatest impact on patient's quality of life, morbidity and healthcare utilization. The study comprised two Phases. In Phase 1, the minimum treatment to control sputum eosinophilia (as well as clinical criteria) in the Sputum Strategy, and clinical criteria in the Clinical Strategy, were established. In Phase 2, this minimum treatment was maintained and patients were seen every 3 momths and at exacerbations. The primary outcomes were the relative risk reduction for the occurrence of the first exacerbation and the length of time without exacerbation over 18-20 months in Phase 2 of the study.
PURPOSE:To provide the titled novel activation agent containing a branched oligosaccharide having alpha-1, 6-bond of glucose molecule, e.g. isomaltose, etc., assimilable selectively only by bifidus bacteria to promote the growth and proliferation of the bacteria and unutilizable by other noxious microorganisms. CONSTITUTION:The objective agent for activating the growth of bifidus bacteria contains a branched oligosaccharide (e.g. isomaltose) having the alpha-1, 6-bond of glucose molecule. The agent is added to a peptone-yeast-Fildes solution (PYF) medium, inoculated with a strain of Bifidobacterium genus and other strain in separated state and cultured under anaerobic condition. The culture liquid is mixed thoroughly and the assimilability is determined by the absorption (turbidity) at 650nm wavelength. It has been recognized that the branched oligosaccharide is unutilizable by microorganisms other than Bifidobacterium genus and is assimilable only by the bifidus bacteria.
A polypeptide comprises at least one IL-1Rrp1 polypeptide linked to at least one AcPL polypeptide. The IL-1Rrp1 polypeptide is encoded by a DNA selected from the group consisting of: a) DNA comprising a nucleotide sequence selected from the group consisting of the coding region of the sequence presented in SEQ ID NO:3 and the coding region of the sequence presented in SEQ ID NO: 7; b) DNA that is complementary to DNA capable of hybridising to the DNA of a). The hybridisation conditions include prewashing with 5X SSC, 0.5% SDS and hybridising at 55oC and 5X SSC and c) DNA that encodes the amino acid sequence presented in SEQ ID NO:4 or that encodes the amino acid sequence presented in SEQ ID NO:8. The AcPL polypeptide is encoded by a DNA selected from the group consisting of: a') DNA comprising a nucleotide sequence selected from the group consisting of the coding region of the sequence presented in SEQ ID NO:1 and the coding region of the sequence presented in SEQ ID NO: 5; b') DNA that is complementary to DNA capable of hybridising to the DNA of a'). The hybridisation conditions include prewashing with 5X SSC, 0.5% SDS and hybridising at 55oC and 5X SSC and c') DNA that encodes the amino acid sequence presented in SEQ ID NO:2 or that encodes the amino acid sequence presented in SEQ ID NO:6.  Also described is a process for preparing the polypeptide, a pharmaceutical composition comprising the polypeptide and its use for inhibiting the effects of IL-18.
Subjects in this parallel arm will be assigned to 13 weeks on Placebo oral solution. Frequency of drug administration is 3-4 times a day.
BACKGROUND: To investigate the association between metabolic syndrome (MetS) and its components with sarcopenia, and to explore the extent to which insulin resistance (IR) mediates this association, using data from the National Health and Nutrition Examination Survey (NHANES).
METHODS: We analyzed cross-sectional data from 15,779 adults in the NHANES from 1999 to 2006 and 2011-2018. Multivariable logistic regression models were used to determine the odds ratios (ORs) between MetS, its components, the number of MetS components, and sarcopenia. Mediation analysis was performed to explore the role of the homeostatic model assessment of insulin resistance (HOMA-IR) in MetS and its components-induced sarcopenia.
RESULT: In the fully adjusted model, MetS increased the prevalence of sarcopenia by 1.96-fold (95% CI: 1.73-2.22). Among the individual components, central obesity, hypertension, and hyperglycemia were associated with an increased prevalence of sarcopenia. Sarcopenia prevalence also increased linearly with the number of MetS components, with the highest prevalence observed in the presence of all five components (OR: 3.80, 95% CI: 2.79-5.16). Sex-stratified analysis showed that the prevalence of MetS for sarcopenia was higher in males than females. The mediating effects of HOMA-IR on the association between MetS and its components (central obesity, hypertension, and hyperglycemia) with sarcopenia were significant, with mediation effects of 51.7%, 30.7%, 33.2%, and 79.1%, respectively. There was no significant direct association between hyperglycemia and sarcopenia beyond the HOMA-IR pathway.
CONCLUSION: MetS and its individual components, excluding hypertriglyceridemia and low high density lipoprotein cholesterol, were associated with a higher prevalence of sarcopenia, especially in males. This association was partially or fully mediated by IR.
UNLABELLED: Herpes simplex viruses (HSV-1 and HSV-2) most commonly cause ulcerative epithelial lesions (cold sores and genital herpes). Importantly, HSV establishes life-long persistent (latent) infection in peripheral neurons. Reactivation from latency produces recurrent epithelial lesions, which constitute the greatest burden of HSV disease in people. The mechanisms that regulate latency and reactivation remain incompletely understood, in part due to limitations in the animal models available for studying HSV reactivation. We have developed a simple and tractable model to induce HSV-1 and HSV-2 reactivation from latency to cause recurrent skin disease. We infected C57BL/6 mice with HSV-1 (strains NS, F, SC16, 17syn+) or HSV-2 (strain 333) on flank skin depilated by manual plucking. After at least 35 days post-infection (dpi), we replucked the fur from the infected flank and observed recurrent lesions in the same dermatome as the primary infection. We detected HSV DNA in dermatome skin through 4 days post-replucking and observed viral antigen and reporter signal in skin lesions by histology, consistent with viral replication following reactivation. In addition to C57BL/6 mice, we were able to produce reactivation in Balb/c and SKH-1 mice. We found that shaving the ipsilateral flank or plucking the contralateral flank did not induce recurrent skin lesions, suggesting that fur plucking is a specific stimulus that induces HSV reactivation. Furthermore, we were able to induce multiple rounds of plucking-induced recurrent disease, providing a model to investigate the lifelong nature of HSV infection. This new model provides a tractable system for studying pathogenic mechanisms of and therapeutic interventions against HSV reactivation and recurrent disease.
IMPORTANCE: Herpes simplex viruses (HSV-1 and HSV-2) have infected over half of the US adult population to cause a lifelong, persistent infection; however, our understanding of the mechanisms that govern HSV reactivation and recurrent disease is incomplete. This is in part due to limitations in the animal models used to study recurrent disease, which are laborious and inefficient in mice. To address this technical gap, we developed a mouse model in which fur plucking after flank skin infection is sufficient to induce episodes of HSV reactivation and recurrent disease. Our work provides a model for the field to investigate the pathogenic mechanisms of HSV and immune responses during recurrent disease and provides an opportunity to investigate the neurobiology of HSV infection.
555,547. Moulding artificial dentures &c. in plaster moulds. AMALGAMATED DENTAL CO., Ltd., and WILDING, S. W. May 14, 1942, No. 6571. [Class 87 (ii)] In a process for making artificial dentures or other models or plaster positives by the use of moulds made from plaster of Paris or other plaster composed mainly of calcium sulphate, the mould is coated with a solution in water of a soluble alginate, such as sodium or potassium alginate. The alginate and calcium sulphate interact to form a film of calcium alginate on the mould which prevents the plaster from sticking to the denture and imparts a smooth surface to the denture, which may be made of polymerized methyl methacrylate. The plaster need not be warmed during the modelling process. To prevent the film of calcium alginate from becoming too dry on exposure to the atmosphere and peeling off the plaster, glycerine, ethylene glycol or other hygroscopic substance may be added to the solution.
Patients affected by breast cancer will have their tissue analysed immediately following their surgical excision for the treatment of breast cancer. Two probes will be used: a linear probe of 4 needle-electrodes positioned in a row that is able to perform Electrical Impedance Spectroscopy (EIS) measurements and a circular probe of 8 needle-electrodes arranged into a circular pattern that is able to generate cross sectional images (Electrical Impedance Tomography maps). Firstly, the linear probe will be inserted in the tumor parenchyma at a penetration depth of about 2 mm and the tissue impedance measurement will be performed along a broad spectrum of frequencies for few minutes. Approximately 10 seconds for each measurement will be needed. Subsequently, if the size of the tissue will allow it, the circular probe will be inserted in the tumor parenchyma at the same penetration depth and 10 cross sectional maps will be generated (approximately 30 seconds in total). Both information obtained using the linear and the circular probes will be integrated for a full characterization of the tissue under examination.
The present invention is directed to implantable and insertable medical devices (also referred to herein as internal medical devices), which contain one or more peroxide-converting catalysts. According to an aspect of the invention, internal medical devices are provided, which contain (a) a substrate and (b) a peptide-containing, peroxide-converting catalyst disposed over at least a portion of the substrate. According to another aspect of the invention, internal medical devices are provided which contain a catalyst binding entity. The catalyst binding entity is adapted to bind to endogenous peroxide-converting catalyst upon implantation or insertion of the devices into patients. In another aspect of the invention, internal medical devices are provided which contain a biodegradable region that in turn contains a peroxide-converting catalyst. These devices release the catalyst in conjunction with degradation of the biodegradable region. In yet another aspect of the invention, internal medical devices are provided which contain a substrate, a multilayer region disposed over at least a portion of the substrate, and a peroxide-converting catalyst disposed within the multilayer region. The multilayer region, in turn, contains a plurality of charged layers of alternating charge, which charged layers further contain a plurality of polyelectrolyte containing layers.
NEW MATERIAL:An oligoribose homocitric acid derivative expressed by the formula (the bonds between the ribose and the ribose are 1  and 1 3 bonds). USE:A preventing agent against a decayed tooth. PROCESS:A microorganism, e.g. Streptomyces sp. MF980-CF1 (FERM-P No. 5430), which belongs to the genus Streptomyces is cultivated in a culture medium, preferably by the liquid spinner culture method with aeration, at 25-30 deg.C for 2-7 days. The produced and accumulated oligoribose homocitric acid derivative is separated and collected.
Patients will be randomized 1:1 to either ShengXian-QuYu Decoction or placebo. "ShengXian-QuYu Decoction" (calculated by a medicine): 30g of Astragalus membranaceus (Huangqi), 12g of Cornus officinalis (Shanzhuyu), 9g of Talinum paniculatum (Jacq.) Gaertn. (Hongshen), 12g of Rhizoma Anemarrhena (Zhimu), 8g of Rhizoma Cimicifugae (Shengma), 8g of Radix Bupleuri (Chaihu), 10g of Platycodon grandiflorum (Jiegeng), 10g of Rhizoma Sparganii (Sanleng), 9g of Rhizoma Curcumae (Ezhu).
HUMALOG has been shown to be equipotent to human insulin on a molar basis. One unit of HUMALOG has the same glucose-lowering effect as one unit of regular human insulin. Studies in normal volunteers and patients with diabetes demonstrated that HUMALOG has a more rapid onset of action and a shorter duration of activity than regular human insulin when given subcutaneously. 

The time course of action of insulin and insulin analogs, such as HUMALOG, may vary considerably in different individuals or within the same individual. The parameters of HUMALOG activity (time of onset, peak time, and duration) as designated in Figure 1 should be considered only as general guidelines. The rate of insulin absorption, and consequently the onset of activity are known to be affected by the site of injection, exercise, and other variables [see Warnings and Precautions (5.2)]. 

Figure 1: Blood Glucose Levels After Subcutaneous Injection of Regular Human Insulin or HUMALOG (0.2 unit/kg) Immediately Before a High Carbohydrate Meal in 10 Patients with Type 1 Diabetesa. 

a Baseline insulin concentration was maintained by infusion of 0.2 mU/min/kg human insulin. 

Intravenous Administration of HUMALOG U-100 — The glucose lowering effect of intravenously administered HUMALOG was tested in 21 patients with type 1 diabetes. For the study, the patients' usual doses of insulin were held and blood glucose concentrations were allowed to reach a stable range of 200 to 260 mg/dL during a one to three hours run-in phase. The run-in phase was followed by a 6-hour assessment phase. During the assessment phase, patients received intravenous HUMALOG at an initial infusion rate of 0.5 units/hour. The infusion rate of HUMALOG could be adjusted at regular timed intervals to achieve and maintain blood glucose concentrations between 100 to 160 mg/dL. 

The mean blood glucose levels during the assessment phase for patients on HUMALOG therapy are summarized below in Table 4. All patients achieved the targeted glucose range at some point during the 6-hour assessment phase. At the endpoint, blood glucose was within the target range (100 to 160 mg/dL) for 17 of 20 patients treated with HUMALOG. The average time (±SE) required to attain near normoglycemia was 129 ± 14 minutes for HUMALOG. 

The pharmacodynamics of a single 20 unit dose of HUMALOG U-200 administered subcutaneously were compared to the pharmacodynamics of a single 20 unit dose of HUMALOG U-100 administered subcutaneously in a euglycemic clamp study enrolling healthy subjects. In this study, the overall, maximum, and time to maximum glucose lowering effect were similar between HUMALOG U-200 and HUMALOG U-100. The mean area under the glucose infusion rate curves (measure of overall pharmacodynamic effect) were 125 g and 126 g for HUMALOG U-200 and HUMALOG U-100, respectively. The maximum glucose infusion rate was 534 mg/min and 559 mg/min and the corresponding median time (min, max) to maximum effect were 2.8 h (0.5 h – 6.3 h) and 2.4 h (0.5 h – 4.7 h) for HUMALOG U-200 and HUMALOG U-100, respectively.
FIELD: medicine. SUBSTANCE: normalizer is essentially biocorrector of processes of energy- information exchange in living and inorganic biologically-active nature. Normalizer consists of two main parts: body and mixture-composite which represents biocorrector used as therapeutic and prophylactic means designed to recover and keep balanced healthy state of man especially at considerable loads. Body, as casing which protects biocorrector, is made either rigid or elastic from material corresponding to sanitary-hygienic requirements. Polystyrene or fluoroplastic (addition of fullerene may be included in composition of these materials) are preferable for use. Shape and profile of body are selected with due regard for profile of pathologic organ projection on epithelial layer. Biocorrector includes mixture of highly biologically- active substances. EFFECT: optimization of physiological characteristics. 4 cl
A needle-guidance system is disclosed including single-patient equipment, multi-patient equipment, and an RFID reader-writer. The single-patient equipment can include a vascular access device (“VAD”) having a needle and an RFID tag. The RFID tag can be incorporated into the VAD or packaging for the VAD. The console can be configured to automatically start needle tracking for a clinician on an integrated display screen of the console after receiving RFID-tag data from the RFID tag and processing with a processor of the console instructions of needle-tracking software provided by memory of the console for the needle tracking. The RFID reader-writer can be configured to read the RFID-tag data from the RFID tag and write additional RFID-tag data to the RFID tag. The RFID reader-writer can be provided with the packaging for the VAD or the multi-patient equipment. A method of the needle-guidance system is also disclosed.
The study included 30 stroke patients. Participants were randomly assigned to two groups: intervention group(n=15) and the control group(n=15). The control group received 45 min of conventional physiotherapy. The intervention group received 45 min of conventional physiotherapy after nonelastic taping, which provides eversion support. The gait balance of both groups was evaluated using the Dynamic Gait Index before and after treatment. . Pre- and post-intervention data were statistically analyzed and compared.
Attending physicians in the intervention arm will receive the following multi-faceted educational intervention on transthoracic echocardiogram appropriateness: 1) a lecture at the beginning of the study period, which describes Appropriate USe Criteria (AUC) and highlights common clinical scenarios for which outpatient echocardiograms are ordered, 2) an electronic "pocket cared" via email that provides tips on appropriate ordering of echocardiograms, and 3) an individualized monthly feedback report that categorizes echocardiograms ordered over the preceding month. The feedback report will contain the number of echocardiograms ordered during the month and how many are classified as appropriate, inappropriate, or uncertain based on the 2011 AUC.
PURPOSE: Gene expressions of vascular Endothelial Growth Factor Alpha (VEGFa), Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B cells (NFkB) and cytokines could be useful for identifying potential therapeutic targets to alleviate ischemia-reperfusion injury after liver transplantation. Cytokine gene expressions, VEGFa and NFkB were investigated in a preclinical swine model of liver transplantation.
METHODS: A total of 12 pigs were used as donors and recipients in liver transplantation without venovenous bypass or aortic clamping. NFkB, IL-6, IL-10, VEGFa and Notch1 gene expression were assessed. These samples were collected in two specific times: group 1 (n= 6) - control, samples were collected before recipient's total hepatectomy and group 2 - liver transplantation group (n=6), where the samples were collected one hour after graft reperfusion.
RESULTS: Liver transplantation was successfully performed in all recipients. Liver enzymes were elevated in the transplantation group. NFkB gene expression was significantly decreased in the transplantation group in comparison with the control group (0.62±0.19 versus 0.39±0.08; p= 0.016). No difference was observed between groups Interleucine 6 (IL-6), interleucine 10 (IL-10), VEGFa and Notch homolog 1 (Notch1).
CONCLUSIONS: In this survey a decreased NFkB gene expression in a porcine model of liver transplantation was observed.
Composed of 30 female patients with glandular lipodystrophy in the buttocks and posterior thigh and fat located in abdomen and flanks that received the treatment of extracorporeal shock waves with energy between 100 and 180mJ, frequency of 15Hz and 6000 shots in abdomen, glutes and thigh Back and flanks 3000 shots with radial applicator and 15mm tip. The treatment is performed twice a week for 1 hour and 30 minutes each session.
The present invention discloses a method and system for conducting interactive rehabilitation session for a user with continuous monitoring. The session for user is generated in form of tasks, using current condition of the user and/or recommendations provided by a physiotherapist. The tasks may be performed by the patient in virtual environment, using, one or more virtual objects. Further, the tasks performed by the user is continuously monitored by implementing image processing techniques. The monitoring is performed to check if the user is performing the tasks as recommended by the physiotherapist. In case a deviation is detected, dynamic feedbacks may be provided to the user in real-time to correct actions of the user. Further, upon ending the sessions, the user may be scored or graded for the session based on performance of the tasks.